 Thyroid Neoplasms
"Thyroid Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the THYROID GLAND.
| Descriptor ID |
D013964
|
| MeSH Number(s) |
C04.588.322.894 C04.588.443.915 C19.344.894 C19.874.788
|
| Concept/Terms |
Thyroid Neoplasms- Thyroid Neoplasms
- Neoplasm, Thyroid
- Thyroid Neoplasm
- Neoplasms, Thyroid
Thyroid Carcinoma- Thyroid Carcinoma
- Carcinoma, Thyroid
- Carcinomas, Thyroid
- Thyroid Carcinomas
- Cancer of Thyroid
- Thyroid Cancers
- Thyroid Cancer
- Cancer, Thyroid
- Cancers, Thyroid
- Cancer of the Thyroid
Thyroid Adenoma- Thyroid Adenoma
- Adenoma, Thyroid
- Adenomas, Thyroid
- Thyroid Adenomas
|
Below are MeSH descriptors whose meaning is more general than "Thyroid Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Thyroid Neoplasms".
This graph shows the total number of publications written about "Thyroid Neoplasms" by people in this website by year, and whether "Thyroid Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 2 | 2 | 4 | | 1998 | 4 | 1 | 5 | | 1999 | 2 | 0 | 2 | | 2000 | 3 | 1 | 4 | | 2001 | 2 | 0 | 2 | | 2002 | 4 | 0 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 7 | 0 | 7 | | 2005 | 1 | 2 | 3 | | 2006 | 8 | 1 | 9 | | 2007 | 1 | 1 | 2 | | 2008 | 5 | 0 | 5 | | 2009 | 7 | 0 | 7 | | 2010 | 10 | 2 | 12 | | 2011 | 1 | 1 | 2 | | 2012 | 5 | 0 | 5 | | 2013 | 9 | 2 | 11 | | 2014 | 9 | 0 | 9 | | 2015 | 15 | 1 | 16 | | 2016 | 7 | 3 | 10 | | 2017 | 10 | 0 | 10 | | 2018 | 14 | 1 | 15 | | 2019 | 6 | 0 | 6 | | 2020 | 7 | 0 | 7 | | 2021 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Thyroid Neoplasms" by people in Profiles.
-
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 08; 22(8):1126-1138.
-
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.
-
Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212.
-
Kwak JJ, Altoos R, Jensen A, Altoos B, McDermott MT. Increased Risk of Radioiodine Treatment Failure Associated with Graves Disease Refractory to Methimazole. Endocr Pract. 2020 Nov; 26(11):1312-1319.
-
French JD. Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies. Nat Rev Endocrinol. 2020 11; 16(11):629-641.
-
Zhou W, Brumpton B, Kabil O, Gudmundsson J, Thorleifsson G, Weinstock J, Zawistowski M, Nielsen JB, Chaker L, Medici M, Teumer A, Naitza S, Sanna S, Schultheiss UT, Cappola A, Karjalainen J, Kurki M, Oneka M, Taylor P, Fritsche LG, Graham SE, Wolford BN, Overton W, Rasheed H, Haug EB, Gabrielsen ME, Skogholt AH, Surakka I, Davey Smith G, Pandit A, Roychowdhury T, Hornsby WE, Jonasson JG, Senter L, Liyanarachchi S, Ringel MD, Xu L, Kiemeney LA, He H, Netea-Maier RT, Mayordomo JI, Plantinga TS, Hrafnkelsson J, Hjartarson H, Sturgis EM, Palotie A, Daly M, Citterio CE, Arvan P, Brummett CM, Boehnke M, de la Chapelle A, Stefansson K, Hveem K, Willer CJ, Åsvold BO. GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer. Nat Commun. 2020 08 07; 11(1):3981.
-
Liyanarachchi S, Gudmundsson J, Ferkingstad E, He H, Jonasson JG, Tragante V, Asselbergs FW, Xu L, Kiemeney LA, Netea-Maier RT, Mayordomo JI, Plantinga TS, Hjartarson H, Hrafnkelsson J, Sturgis EM, Brock P, Nabhan F, Thorleifsson G, Ringel MD, Stefansson K, de la Chapelle A. Assessing thyroid cancer risk using polygenic risk scores. Proc Natl Acad Sci U S A. 2020 03 17; 117(11):5997-6002.
-
Papoian V, Rosen JE, Lee W, Wartofsky L, Felger EA. Differentiated thyroid cancer and Hashimoto thyroiditis: Utility of the Afirma gene expression classifier. J Surg Oncol. 2020 Jun; 121(7):1053-1057.
-
Richard MA, Lupo PJ, Morton LM, Yasui YA, Sapkota YA, Arnold MA, Aubert G, Neglia JP, Turcotte LM, Leisenring WM, Sampson JN, Chanock SJ, Hudson MM, Armstrong GT, Robison LL, Bhatia S, Gramatges MM. Genetic variation in POT1 and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. PLoS One. 2020; 15(2):e0228887.
-
Sawka AM, Gagliardi AR, Haymart MR, Sturgeon C, Bernet V, Hoff K, Angelos P, Brito JP, Haugen BR, Kim B, Kopp PA, Mandel SJ, Ross DS, Samuels M, Sarne D, Sinclair C, Jonklaas J. A Survey of American Thyroid Association Members Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines. Thyroid. 2020 01; 30(1):25-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|